Researchers found that by dosing study participants with a weakened, early developmental form of the parasite responsible for transferring malaria, they could trigger immunity to the disease for as much as a year in adults. Previous studies reported malaria vaccine effectiveness lasting for at least a few weeks.
“These results are really important,” Kirsten E. Lyke, MD, a researcher at the University of Maryland School of Medicine in Baltimore, said in a statement. “Malaria has such a devastating effect on children, especially in Africa. This vaccine has the potential to help travelers, military personnel and children in malaria-endemic areas.”
After being inoculated, participants were bitten by mosquitoes carrying the full-blown version of the same strain of parasite used in the vaccine. Overall, more than half of the participants who received a vaccine and were subsequently bitten were protected from developing malaria for up to a year. The protected participants were also unable to transmit the disease during that time.
The results of the Phase 1 trial are published in Nature Medicine.
More articles on vaccines:
Physician access to vaccine records linked to higher immunization rates
Flu vaccine produces better outcomes when administered in the morning
Zika vaccine testing could begin in September
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.